id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
DEA-2016-0014-0005,DEA,DEA-2016-0014,Thiafentanil HHS Supplemental Info_March 2016,Supporting & Related Material,,2016-08-26T04:00:00Z,2016,8,,,2016-08-26T12:27:38Z,,0,0,090000648219eefc
DEA-2016-0014-0001,DEA,DEA-2016-0014,Schedules of Controlled Substances: Placement of Thiafentanil into Schedule II,Rule,,2016-08-26T04:00:00Z,2016,8,2016-08-26T04:00:00Z,2016-09-27T03:59:59Z,2016-09-22T01:00:54Z,2016-20463,0,0,090000648219f4c0
DEA-2016-0014-0003,DEA,DEA-2016-0014,Thiafentanil DEA 8-factor_Aug 2016,Supporting & Related Material,,2016-08-26T04:00:00Z,2016,8,,,2016-08-26T12:27:33Z,,0,0,090000648219e1fa
DEA-2016-0014-0002,DEA,DEA-2016-0014,FDA Letter to Mr. Rosenberg 6-20-16,Supporting & Related Material,,2016-08-26T04:00:00Z,2016,8,,,2016-08-26T12:27:30Z,,0,0,090000648219e1f9
DEA-2016-0014-0004,DEA,DEA-2016-0014,Thiafentanil HHS 8-Factor_Nov 2011,Supporting & Related Material,,2016-08-26T04:00:00Z,2016,8,,,2016-08-26T12:27:35Z,,0,0,090000648219eefb